DSI
AGIO icon

Daiwa SB Investments’s Agios Pharmaceuticals AGIO Stock Holding History

Daiwa SB Investments’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-3,311
Closed -$170K – 240
2017
Q2 		$170K Sell
3,311
-459
-12% -$23.5K 0.05% 126
2017
Q1 		$220K Sell
3,770
-2,030
-35% -$97.3K 0.06% 121
2016
Q4 		$242K Sell
5,800
-2,428
-30% -$127K 0.06% 121
2016
Q3 		$435K Buy
+8,228
New +$358K 0.11% 111

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Daiwa SB Investments's AGIO Position: Q3 2017 in Review

Daiwa SB Investments sold out of Agios Pharmaceuticals (AGIO) in Q3 2017, closing a stake of 3,311 shares — an estimated $170K sold.

Daiwa SB Investments first reported a position in AGIO in Q3 2016 and held it in 4 quarters. The position peaked at $435K in Q3 2016. 171 funds tracked by Wall St. Rank hold AGIO as of Q3 2017.

  • Daiwa SB Investments reported no remaining Agios Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Daiwa SB Investments sold 3,311 Agios Pharmaceuticals shares in Q3 2017, an estimated $170K.
  • Daiwa SB Investments first reported a position in Agios Pharmaceuticals in Q3 2016 and held it in 4 quarters.
  • Daiwa SB Investments's Agios Pharmaceuticals position peaked at $435K in Q3 2016.
  • 171 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2017.

Based on Daiwa SB Investments's 13F filing for Q3 2017, filed 13 Oct 2017.